Science Explorer Back to mapMap

Most cited papers from Springer Nature (New Zealand)

What are the most cited papers from Springer Nature (New Zealand)?

The most cited paper from Springer Nature (New Zealand) is "Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations" (Don Husereau, Michael Drummond, Federico Augustovski et al., 2022), with 1,117 citations. Next come "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force" (888) and "Patisiran: First Global Approval" (620).

Showing 50 of 56 papers. Every paper with more than 197 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations Don Husereau, Michael Drummond, Federico Augustovski et al. · Value in Health Open access 2022 1,117
2 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force Don Husereau, Michael Drummond, Federico Augustovski et al. · Value in Health Open access 2022 888
3 Patisiran: First Global Approval Sheridan M. Hoy · Drugs 24 Sep 2018 620
4 BNT162b2 mRNA COVID-19 Vaccine: First Approval Yvette N. Lamb · Drugs Open access Mar 2021 437
5 Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting Gillian M. Keating · Drugs 10 Jun 2015 436
6 Givosiran: First Approval Lesley J. Scott · Drugs Feb 2020 423
7 Tocilizumab: A Review in Rheumatoid Arthritis Lesley J. Scott · Drugs Open access Nov 2017 423
8 Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections Matt Shirley · Drugs Apr 2018 389
9 Inclisiran: First Approval Yvette N. Lamb · Drugs Open access Feb 2021 361
10 Resmetirom: First Approval Susan J. Keam · Drugs Open access 21 May 2024 354
11 Tazemetostat: First Approval Sheridan M. Hoy · Drugs 12 Mar 2020 344
12 Onasemnogene Abeparvovec: First Global Approval Sheridan M. Hoy · Drugs Jul 2019 344
13 Lenvatinib: A Review in Hepatocellular Carcinoma Zaina T. Al-Salama, Yahiya Y. Syed, Lesley J. Scott · Drugs Apr 2019 337
14 Sorafenib: A Review in Hepatocellular Carcinoma Gillian M. Keating · Targeted Oncology 15 Mar 2017 318
15 Golodirsen: First Approval Young‐A Heo · Drugs Feb 2020 317
16 Osimertinib: First Global Approval Sarah L. Greig · Drugs 4 Jan 2016 316
17 Nirmatrelvir Plus Ritonavir: First Approval Yvette N. Lamb · Drugs Open access 19 Mar 2022 311
18 Tofacitinib: A Review in Rheumatoid Arthritis Sohita Dhillon · Drugs 14 Nov 2017 301
19 Nusinersen: First Global Approval Sheridan M. Hoy · Drugs 22 Feb 2017 298
20 Lumasiran: First Approval Lesley J. Scott, Susan J. Keam · Drugs 6 Jan 2021 297
21 Sacituzumab Govitecan: First Approval Yahiya Y. Syed · Drugs Open access 11 Jun 2020 296
22 Remdesivir: First Approval Yvette N. Lamb · Drugs Open access Sep 2020 294
23 Aducanumab: First Approval Sohita Dhillon · Drugs 29 Jul 2021 293
24 Anlotinib: First Global Approval Yahiya Y. Syed · Drugs 26 Jun 2018 291
25 Casimersen: First Approval Matt Shirley · Drugs 16 Apr 2021 286
26 Alpelisib: First Global Approval Anthony Markham · Drugs 29 Jun 2019 278
27 Camrelizumab: First Global Approval Anthony Markham, Susan J. Keam · Drugs 16 Jul 2019 274
28 Trastuzumab Deruxtecan: First Approval Susan J. Keam · Drugs 7 Mar 2020 273
29 Roxadustat: First Global Approval Sohita Dhillon · Drugs 25 Feb 2019 258
30 Caplacizumab: First Global Approval Sean T. Duggan · Drugs Open access Oct 2018 253
31 Pexidartinib: First Approval Yvette N. Lamb · Drugs Open access 10 Oct 2019 252
32 Venetoclax: First Global Approval Emma D. Deeks · Drugs Jun 2016 244
33 Dapagliflozin: A Review in Type 2 Diabetes Sohita Dhillon · Drugs Open access 25 Jun 2019 242
34 Pemigatinib: First Approval Sheridan M. Hoy · Drugs 29 May 2020 241
35 Larotrectinib: First Global Approval Lesley J. Scott · Drugs 11 Jan 2019 241
36 Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers Lesley J. Scott · Drugs 16 Apr 2018 239
37 Eteplirsen: First Global Approval Yahiya Y. Syed · Drugs Nov 2016 232
38 Sotorasib: First Approval Hannah A. Blair · Drugs Open access 6 Aug 2021 230
39 Viltolarsen: First Approval Sohita Dhillon · Drugs 9 Jun 2020 227
40 Polatuzumab Vedotin: First Global Approval Emma D. Deeks · Drugs Open access 27 Jul 2019 223
41 Volanesorsen: First Global Approval Julia Paik, Sean T. Duggan · Drugs 12 Jul 2019 219
42 Pitolisant: A Review in Narcolepsy with or without Cataplexy Yvette N. Lamb · CNS Drugs 29 Jan 2020 217
43 Baloxavir: First Global Approval Young‐A Heo · Drugs Apr 2018 214
44 Sintilimab: First Global Approval Sheridan M. Hoy · Drugs Feb 2019 210
45 Fexinidazole: First Global Approval Emma D. Deeks · Drugs 11 Jan 2019 210
46 Pretomanid: First Approval Susan J. Keam · Drugs 3 Oct 2019 208
47 Pyrotinib: First Global Approval Hannah A. Blair · Drugs 19 Oct 2018 205
48 Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer Yvette N. Lamb, Sohita Dhillon · Molecular Diagnosis & Therapy 2 Feb 2017 204
49 Telitacicept: First Approval Sohita Dhillon · Drugs 31 Aug 2021 202
50 Talazoparib: First Global Approval Sheridan M. Hoy · Drugs 30 Nov 2018 202

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.